Amendments to Memorandum of Association
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals' board has approved two key changes on 14th May 2025. First, the company is expanding its Main Objects clause in the MOA to enter new business areas including general trading of goods, real estate development and construction, property management and leasing, consulting services, and jewellery/precious metals business — a significant diversification away from its pharmaceutical roots. Second, the authorised share capital is being increased from ₹116 Crore (11.6 crore equity shares of ₹10 each) to ₹186 Crore (18.6 crore equity shares of ₹10 each), a 60% jump. Both changes are subject to shareholder approval. The new objects are unusually broad, covering everything from bullion trading to amusement parks.
Shareholders should note this signals a major potential diversification beyond pharma. The capital increase creates headroom for future fundraising (rights issue, preferential allotment, or QIP), which could lead to dilution. Investors may want to seek clarity on the strategic rationale and capital-raising plans before approving these changes.